Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

ARA-290 / Cibinetide.

Research draft

Cibinetide, also called ARA-290, is an erythropoietin-derived tissue-protective peptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Cibinetide, also called ARA-290, is an erythropoietin-derived tissue-protective peptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It was designed to engage repair-related receptor signalling without erythropoietin's red-cell-stimulating effect.

Human research

Randomised sarcoidosis-associated small-fibre neuropathy research examined nerve measures and symptoms; this does not establish broad nerve repair.

Preclinical & other research

Animal work investigated inflammatory injury and tissue protection.

Safety & unknowns

Limited trial size and disease specificity restrict conclusions about long-term safety and other uses.

Regulatory status

Investigational; no broad neuropathy approval is established by these studies.

Reported use & evidence

Research profile draft

The supplied ARA-290 / Cibinetide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds